Last reviewed · How we verify

Atazanvir/ritonavir + efavirenz

Bristol-Myers Squibb · Phase 3 active Small molecule

Atazanvir/ritonavir + efavirenz is a Antiretroviral combination (protease inhibitor + NNRTI) Small molecule drug developed by Bristol-Myers Squibb. It is currently in Phase 3 development for HIV-1 infection in treatment-naïve and treatment-experienced patients. Also known as: Reyataz & Sustiva.

This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.

This combination inhibits HIV protease and reverse transcriptase to suppress viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.

At a glance

Generic nameAtazanvir/ritonavir + efavirenz
Also known asReyataz & Sustiva
SponsorBristol-Myers Squibb
Drug classAntiretroviral combination (protease inhibitor + NNRTI)
TargetHIV protease, HIV reverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Atazanavir is a protease inhibitor that blocks HIV protease, preventing the maturation of viral particles. Ritonavir is a pharmacokinetic booster that inhibits cytochrome P450 metabolism, increasing atazanavir levels. Efavirenz is a non-nucleoside reverse transcriptase inhibitor that blocks the enzyme required for HIV RNA conversion to DNA. Together, these three agents target multiple steps in the HIV replication cycle.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Atazanvir/ritonavir + efavirenz

What is Atazanvir/ritonavir + efavirenz?

Atazanvir/ritonavir + efavirenz is a Antiretroviral combination (protease inhibitor + NNRTI) drug developed by Bristol-Myers Squibb, indicated for HIV-1 infection in treatment-naïve and treatment-experienced patients.

How does Atazanvir/ritonavir + efavirenz work?

This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.

What is Atazanvir/ritonavir + efavirenz used for?

Atazanvir/ritonavir + efavirenz is indicated for HIV-1 infection in treatment-naïve and treatment-experienced patients.

Who makes Atazanvir/ritonavir + efavirenz?

Atazanvir/ritonavir + efavirenz is developed by Bristol-Myers Squibb (see full Bristol-Myers Squibb pipeline at /company/bristol-myers-squibb).

Is Atazanvir/ritonavir + efavirenz also known as anything else?

Atazanvir/ritonavir + efavirenz is also known as Reyataz & Sustiva.

What drug class is Atazanvir/ritonavir + efavirenz in?

Atazanvir/ritonavir + efavirenz belongs to the Antiretroviral combination (protease inhibitor + NNRTI) class. See all Antiretroviral combination (protease inhibitor + NNRTI) drugs at /class/antiretroviral-combination-protease-inhibitor-nnrti.

What development phase is Atazanvir/ritonavir + efavirenz in?

Atazanvir/ritonavir + efavirenz is in Phase 3.

What are the side effects of Atazanvir/ritonavir + efavirenz?

Common side effects of Atazanvir/ritonavir + efavirenz include Nausea, Diarrhea, Headache, Dizziness, Rash, Hyperbilirubinemia.

What does Atazanvir/ritonavir + efavirenz target?

Atazanvir/ritonavir + efavirenz targets HIV protease, HIV reverse transcriptase and is a Antiretroviral combination (protease inhibitor + NNRTI).

Related